Cellectar Biosciences Strengthens Intellectual Property Protection For Its PDC Platform
Portfolio Pulse from Benzinga Newsdesk
Cellectar Biosciences, Inc. (NASDAQ:CLRB) has received Notice of Allowance for a patent on its Phospholipid Drug Conjugate (PDC) platform from patent authorities in Japan, China, Eurasia, Brazil, and Mexico. This follows previous allowances in the US, Europe, Australia, and Canada. The patent covers the composition and use of PDCs with flavaglines for targeted cancer therapy. The company plans to report pivotal data for its lead radioconjugate therapy in January 2024 and is working on expanding its pipeline of PDCs for high need cancers.
December 12, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cellectar Biosciences has strengthened its intellectual property position with patent allowances in multiple key global regions for its PDC platform, which is crucial for its cancer treatment therapies.
The receipt of patent allowances in several key markets significantly strengthens Cellectar Biosciences' intellectual property portfolio, which is likely to have a positive impact on investor confidence and the company's ability to protect its technology. This could lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100